Cipla Limited has announced its audited financial results for the quarter and year ended March 31, 2026, reporting a record annual revenue of ₹28,163 crore. Despite a challenging global environment, the company achieved double-digit growth in its One-India business and secured approval for its first AB-rated gVentolin in North America. The Board has recommended a final dividend of ₹13 per equity share for the financial year.
Financial Performance Overview
For the full financial year FY26, Cipla achieved a total income of ₹28,163 crore, marking a significant milestone for the company. While the fourth quarter (Q4) saw a total income of ₹6,541 crore, the annual performance reflects the underlying strength of the firm’s core business sectors. The company reported a FY26 EBITDA of ₹5,925 crore with a margin of 21.0%, and a PAT of ₹3,879 crore.
Key Business Segment Highlights
The One-India business emerged as a standout performer, growing 15% year-on-year during the final quarter, with the branded prescription segment sustaining momentum in chronic therapies. The North America division reported annual revenue of $780 million, bolstered by a differentiated portfolio. A major highlight for this region was the regulatory approval for the first AB-rated gVentolin with CGT, representing a significant technological advancement for the company’s US manufacturing facility.
Additionally, the Emerging Markets and Europe segment surpassed the $400 million annual revenue threshold, demonstrating resilience against geopolitical uncertainties. Meanwhile, the One Africa business maintained a healthy growth trajectory with a 7% annual increase in USD terms.
Shareholder Returns and Operational Updates
In recognition of the company’s performance, the Board of Directors has recommended a final dividend of ₹13 per equity share, having a face value of ₹2 each. This proposal is pending approval from shareholders at the upcoming annual general meeting.
On the operational front, Cipla continues to invest in innovation, with R&D expenditure reaching ₹509 crore, or 7.8% of sales, in the fourth quarter. The company also reported a net cash position of ₹10,526 crore, providing a solid foundation for future growth and pipeline development. Furthermore, recent inspections by the USFDA across key manufacturing sites in Bengaluru, Navi Mumbai, and Goa have resulted in favorable ‘VAI’ or ‘NAI’ classifications.
Source: BSE
